comparemela.com
Latest Breaking News On - Uprolesan - Page 1 : comparemela.com
Uproleselan Plus Chemotherapy Misses Phase 3 Trial OS End Point in R/R AML
Uproleselan plus chemotherapy did not achieve a statistically significant improvement in OS vs chemotherapy alone in patients with relapsed/refractory AML.
China
United-states
Chinese
Harout-semerjian
Chinese-national-medical-products-administration
National-cancer-institute
Alliance-for-clinical-trials-in-oncology
Clinical-trials
Hematologic-oncology
News
Acute-myeloid-leukemia
Uprolesan
vimarsana © 2020. All Rights Reserved.